BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3260466)

  • 1. [Adoptive immunotherapy of malignant disease using LAK cells].
    Kimoto Y; Taguchi T
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):788-96. PubMed ID: 3260466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
    Kimoto Y; Taguchi T
    Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [LAK cells and cancer].
    Taguchi T; Kimoto Y
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adoptive immunotherapy of malignant diseases with LAK cells].
    Kimoto Y; Tanji Y; Tanaka T; Taguchi T
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):687-92. PubMed ID: 3493732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
    Taguchi T; Domoto K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
    Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
    Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
    Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique.
    Favrot MC; Coze C; Combaret V; Gaspard M; Colin C; Franks C; Negrier S; Philip I; Philip T
    Mol Biother; 1990 Mar; 2(1):32-7. PubMed ID: 2185792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
    Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].
    Okamoto Y; Shimizu K; Miyao Y; Yamada M; Ushio Y; Matsui Y; Hayakawa T; Tago H; Ikeda H
    No To Shinkei; 1986 Jun; 38(6):593-8. PubMed ID: 3488068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
    Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of pericarditis carcinomatosa showing good response following local transfer of lymphokine-activated killer (LAK) cells].
    Ueno Y; Kohgo Y; Sasagawa Y; Kanisawa Y; Nojiri S; Mahara K; Niitsu Y; Maekawa S; Oguma K; Urushizaki I
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2579-82. PubMed ID: 3497613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.